Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to estimate the effect of CYP3A4*22 on the clearance and area
under the plasma concentration-time curve of Palbociclib, Ribociclib, and Abemaciclib